We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

13 hedge funds and large institutions have $22.2M invested in Bellerophon Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more capital invested

Capital invested by funds: $8.35M → $22.2M (+$13.8M)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

13% less funds holding

Funds holding: 15 → 13 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$364K
2
Renaissance Technologies
Renaissance Technologies
New York
+$250K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$134K
4
Goldman Sachs
Goldman Sachs
New York
+$88K
5
Northern Trust
Northern Trust
Illinois
+$60.8K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$520K
2
SM
Sabby Management
Florida
-$414K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$80K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.2K
5
Citadel Advisors
Citadel Advisors
Florida
-$10.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMVA
1
New Mountain Vantage Advisers
New York
$15.8M – – –
BC
2
Boxer Capital
California
$2.77M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$1.7M -$68.2K -4,340 -5%
Renaissance Technologies
4
Renaissance Technologies
New York
$711K +$250K +15,887 +100%
Vanguard Group
5
Vanguard Group
Pennsylvania
$598K +$364K +23,188 +648%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$190K +$134K +8,533 New
LPL Financial
7
LPL Financial
California
$150K +$3.14K +200 +3%
Goldman Sachs
8
Goldman Sachs
New York
$125K +$88K +5,600 New
Northern Trust
9
Northern Trust
Illinois
$86K +$60.8K +3,866 New
Creative Planning
10
Creative Planning
Kansas
$28K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$27K -$10.7K -682 -36%
GA
12
Geneva Advisors
Illinois
$19K – – –
Morgan Stanley
13
Morgan Stanley
New York
$1K – – –
AC
14
Armistice Capital
New York
– -$520K -66,667 Closed
SM
15
Sabby Management
Florida
– -$414K -52,657 Closed
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
– -$80K -10,286 Closed
VKH
17
Virtu KCG Holdings
New York
– -$6K -773 Closed

BLPH Hedge Fund Activity: Q1 2017 in Review

13 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2017, worth a combined $22.2M — up 165% from $8.35M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BLPH and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $364K. The largest seller was Armistice Capital, exiting entirely with an estimated $520K sold.

  • 13 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2017, down from 15 in Q4 2016.
  • Funds reported $22.2M of Bellerophon Therapeutics, Inc. stock for Q1 2017, up 165% quarter-over-quarter.
  • 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2017 and 5 closed out, a net change of -2 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q1 2017 was Vanguard Group, an estimated $364K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q1 2017 was Armistice Capital, an estimated $520K sold.

Based on aggregated 13F filings for Q1 2017.